SI
BMRN icon

Stephens Inc’s BioMarin Pharmaceuticals BMRN Stock Holding History

Stephens Inc’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,665
Closed -$235K – 1325
2021
Q4 		$235K Sell
2,665
-527
-17% -$43.5K ﹤0.01% 1142
2021
Q3 		$247K Sell
3,192
-409
-11% -$32.3K ﹤0.01% 1127
2021
Q2 		$300K Buy
3,601
+296
+9% +$23.5K ﹤0.01% 1034
2021
Q1 		$250K Sell
3,305
-849
-20% -$69.4K ﹤0.01% 1077
2020
Q4 		$364K Sell
4,154
-234
-5% -$18.6K 0.01% 862
2020
Q3 		$334K Buy
4,388
+159
+4% +$16.1K 0.01% 840
2020
Q2 		$522K Sell
4,229
-697
-14% -$69.3K 0.01% 686
2020
Q1 		$416K Sell
4,926
-56
-1% -$4.83K 0.01% 694
2019
Q4 		$421K Buy
4,982
+832
+20% +$62.8K 0.01% 774
2019
Q3 		$280K Sell
4,150
-90
-2% -$6.93K 0.01% 935
2019
Q2 		$363K Buy
4,240
+966
+30% +$82.6K 0.01% 846
2019
Q1 		$291K Sell
3,274
-166
-5% -$15.4K 0.01% 927
2018
Q4 		$293K Buy
3,440
+296
+9% +$28.2K 0.01% 857
2018
Q3 		$305K Buy
+3,144
New +$314K 0.01% 924

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Stephens Inc's BMRN Position: Q1 2022 in Review

Stephens Inc sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 2,665 shares — an estimated $235K sold.

Stephens Inc first reported a position in BMRN in Q3 2018 and held it in 14 quarters. The position peaked at $522K in Q2 2020. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

  • Stephens Inc reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Stephens Inc sold 2,665 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $235K.
  • Stephens Inc first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 14 quarters.
  • Stephens Inc's BioMarin Pharmaceuticals position peaked at $522K in Q2 2020.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Stephens Inc's 13F filing for Q1 2022, filed 4 May 2022.